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Peripheral neuropathic pain arises as a consequence of injury to sensory neurons; the development of ectopic activity in these neurons
is thought to be critical for the induction and maintenance of such pain. Local anaesthetics and anti-epileptic drugs can suppress
hyperexcitability; however, these drugs are complicated by unwanted effects on motor, central nervous system and cardiac function,
and alternative more selective treatments to suppress hyperexcitability are therefore required. Here we show that a glutamate-gated
chloride channel modiﬁed to be activated by low doses of ivermectin (but not glutamate) is highly effective in silencing sensory
neurons and reversing neuropathic pain-related hypersensitivity. Activation of the glutamate-gated chloride channel expressed in either
rodent or human induced pluripotent stem cell-derived sensory neurons in vitro potently inhibited their response to both electrical and
algogenic stimuli. We have shown that silencing is achieved both at nerve terminals and the soma and is independent of membrane
hyperpolarization and instead likely mediated by lowering of the membrane resistance. Using intrathecal adeno-associated virus
serotype 9-based delivery, the glutamate-gated chloride channel was successfully targeted to mouse sensory neurons in vivo, resulting
in high level and long-lasting expression of the channel selectively in sensory neurons. This enabled reproducible and reversible
modulation of thermal and mechanical pain thresholds in vivo; analgesia was observed for 3 days after a single systemic dose of
ivermectin. We did not observe any motor or proprioceptive deﬁcits and noted no reduction in cutaneous afferent innervation or
upregulation of the injury marker ATF3 following prolonged glutamate-gated chloride channel expression. Established mechanical
and cold pain-related hypersensitivity generated by the spared nerve injury model of neuropathic pain was reversed by ivermectin
treatment. The efﬁcacy of ivermectin in ameliorating behavioural hypersensitivity was mirrored at the cellular level by a cessation of
ectopic activity in sensory neurons. These ﬁndings demonstrate the importance of aberrant afferent input in the maintenance of
neuropathic pain and the potential for targeted chemogenetic silencing as a new treatment modality in neuropathic pain.
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Introduction
Neuropathic pain arises as a consequence of a lesion or
disease of the somatosensory nervous system and affects
7–10% of the general population (Colloca et al., 2017).
Many of the most common causes of neuropathic pain
such as post-herpetic neuralgia, diabetic polyneuropathy
and traumatic nerve injury, relate to injury to sensory neu-
rons within the peripheral nervous system. A key patho-
physiological driver for the induction and maintenance of
neuropathic pain in such conditions is the development of
hyperexcitability of sensory neurons, which develop ectopic
activity (Wall and Gutnick, 1974; Wall and Devor, 1983;
Kajander and Bennett, 1992; Boucher et al., 2000; Wu
et al., 2001) and an abnormal response to natural stimuli
(Shim et al., 2005; Smith et al., 2013). Such abnormalities
have been demonstrated in multiple animal models of per-
ipheral nerve injury (Kajander and Bennett, 1992; Boucher
et al., 2000; Wu et al., 2001) as well as in patients suffering
from peripheral neuropathic pain through the use of micro-
neurography (Serra et al., 2012). Ectopic activity develops
in small diameter unmyelinated and large diameter myelin-
ated sensory axons, and arises at the site of the injured
axon and at the level of the cell body (Wall and Devor,
1983). This hyperexcitability occurs due to profound
changes in the expression as well as altered trafﬁcking
and post-translational modiﬁcations of ion channels
within sensory neurons (Waxman and Zamponi, 2014).
Studies on patients using local anaesthetic blocks suggest
that abnormal afferent input from sensory neurons is
required for the maintenance of peripheral neuropathic pain
(Haroutounian et al., 2014; Vaso et al., 2014). Systemic
lidocaine reduces ectopic activity in animal models of nerve
injury (Devor et al., 1992); however, dose escalation in
humans is limited by motor, cardiac and CNS side effects.
Similarly, the oral analgesics currently available that target
aberrant afferent input have limited efﬁcacy and poor
tolerability (Finnerup et al., 2015).
Chemogenetics provides opportunities for a novel treat-
ment approach to neuropathic pain by silencing aberrant
primary afferent input. This technique enables precise con-
trol of neuronal activity through expression of receptors/
ion channels that have been engineered to be solely acti-
vated by a non-toxic drug (Sternson and Roth, 2014). This
allows for temporal and spatial control of activity, deter-
mined by the pattern of expression of the receptor and
timing of drug administration. From a translational per-
spective, a key attribute of the chemogenetic approach is
that it enables non-invasive and chronic modulation of
neuronal activity. A heteromeric glutamate-gated chloride
channel (GluCl v1.0) modiﬁed to respond to low doses of
ivermectin but not glutamate, has previously been shown
to silence activity of mammalian CNS neurons in vivo for
several days following a single dose of ivermectin (Lerchner
et al., 2007; Lin et al., 2011). Effectiveness was limited by
difﬁculties of ivermectin crossing the blood–brain barrier
and suboptimal b-subunit trafﬁcking (Lerchner et al.,
2007). We therefore used a recently optimized version of
GluCl (GluCl v2.0), wherein ivermectin sensitivity and ef-
fective trafﬁcking of the b-subunit have been increased
(Frazier et al., 2013) with the aim of silencing peripheral
sensory neurons.
Materials and methods
Animals
Young (4–8-week-old) wild-type C57BL/6 mice (University of
Oxford Breeding Unit) of both genders were used for in vitro
culture experiments including electrophysiology, somal Ca2+
imaging and immunocytochemistry. Adult male (6–8 weeks
old at time of intrathecal surgery) C57BL/6 mice were used
for all behavioural experiments. For microﬂuidic experiments,
embryonic Day 16 Sprague-Dawley rat embryos (Charles River)
were used. Animals were group-housed in speciﬁc pathogen-free
conditions on a 12:12 h light–dark cycle at 23  1C with free
access to food and water. All behavioural testing was performed
during the light phase. Animals were assigned to treatment
groups by randomly drawing them from their housing cages
and rehoused post-treatment in mixed cages. All procedures
complied with the UK Animals (Scientiﬁc Procedures) Act
(1986) and were performed under a UK Home Ofﬁce Project
Licence in accordance with University of Oxford Policy on the
Use of Animals in Scientiﬁc Research. This study conforms to
the ARRIVE guidelines (Kilkenny et al., 2013).
Plasmids and AAV production
Control (GFP) plasmid was pAcGFP1-C1 (Clonetech
Laboratories). Constructs for GluCl v2.0 (Opt a-GluClv2.0
and Opt b-GluClv2.0) were a gift from Henry Lester
(Addgene plasmids 47387 and 47542) (Frazier et al., 2013).
The yellow ﬂuorescence protein (YFP) sequence of a-
GluClv2.0 was replaced by the sequence for monomeric
Cerulean (mCerulean; Rizzo et al., 2004) (gift from Dave
Piston, Addgene plasmid 15214) using EcoRI cloning sites.
a- and b-GluCl transgenes were excised and inserted separately
into a pAAV (adeno-associated virus) packaging plasmid with
the use of BamHI/NotI (b) and HindIII/NotI (a) restriction
sites. The packaging plasmid contained the inverted terminal
repeats of AAV2 ﬂanking a 1.8 kb CAG promoter, the trans-
gene and a bovine growth hormone (bGH) polyadenylation
signal. Constructs were commercially packaged and serotyped
with the AAV9 capsid protein by Penn Vector Core in the
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Gene Therapy Program of the University of Pennsylvania to a
ﬁnal titre of 2.4  1013 gene copies (GC)/ml (GluClb-AAV)
and 1.5  1013 GC/ml (GluCla-AAV).
Surgical procedures
Intrathecal delivery of AAV was performed on 6–8-week-old
mice (18–25 g) under 2% inhaled isoﬂurane anaesthesia. The
dura was exposed by careful dissection of soft tissue between
T10 and T11 vertebrae and punctured with a 30G needle,
before a small cannula (polyetraﬂuoroethylene tubing, 0.008”
outer diameter  0.004” internal diameter, Braintree Scientiﬁc)
was inserted 1 cm caudally into the subarachnoid space. Eight
microlitres of AAV [4 ml of neat GluClb-AAV with 4ml of neat
GluCla-AAV, or phosphate-buffered saline (PBS)] was then
infused at a rate of 1ml/min. Following a 1-min rest period
to limit backﬂow, the cannula was slowly removed and the
animal recovered with the administration of local (2mg/kg
Marcain, AstraZeneca) and systemic (5mg/kg Rimadyl,
Pﬁzer) postoperative analgesia. The time between intrathecal
infusion and animal sacriﬁce to assess viral transduction or
the commencement of behavioural analysis was at least
3 weeks.
For the spared nerve injury (SNI) model we ligated and tran-
sected the tibial and common peroneal branches of the sciatic
nerve, leaving the sural nerve intact (Decosterd and Woolf,
2000). Animals received postoperative analgesia as detailed
above and were assessed behaviourally from 3 days post-SNI
in addition to being monitored for self-mutilation (autotomy)
daily. Autotomy of two or more nails/toes led us to sacriﬁce
the animal. Any animals that did not show a 50% reduction in
mechanical thresholds by 7 days post-SNI were excluded from
further assessment and were not included in the ﬁnal analysis.
The presence of autotomy or the lack of mechanical hypersen-
sitivity led us to exclude 2/30 animals. For whole-cell patch
clamp experiments L3, L4 and L5 dorsal root ganglia (DRG)
were pooled from animals that had undergone SNI surgery
3–5 weeks previously to generate DRG cell cultures
(see below).
Ivermectin intraperitoneal injections
A 1% sterile solution of ivermectin (Noromectin, Norbrook
Laboratories) was diluted to 0.5% in sterile propylene glycol,
prior to intraperitoneal (i.p.) injection at 1 ml/g animal body
weight.
Behavioural testing
All behavioural studies were performed by an experimenter
blind to treatment group and at a consistent time of day.
Sample sizes were chosen based on similar experiments in the
literature (thermal place preference experiments; Bautista et al.,
2007), or calculated using standard power calculations based on
our own previous studies (statistical power of 80% and a-
value50.05). For assessment of mechanical and thermal
thresholds the minimum group size required to show a 25%
change was 9 and the group size required to detect a 25%
rescue in mechanical sensitivity following SNI was 8.
Application of von Frey hair ﬁlaments (Stoelting) to the plantar
surface of the hind paw using the ‘up-down’ method was used
to assess mechanical sensitivity. Prior to testing, mice were
acclimatized for 1h on an elevated wire mesh ﬂoor and
housed in 8  5  10-cm partitions. The 50% paw-withdrawal
threshold was calculated as per Dixon (1980) on three different
days and the average taken as the baseline value. Thermal
thresholds were assessed using an infrared light source applied
to the plantar surface of each hind paw (Hargreaves test).
Latency to withdraw was tested three times per paw and aver-
aged. All baseline data represent the average score of three sep-
arate days of testing. Except in the case of nerve injury, all
sensory threshold data represent the average of right and left
hind paws. Noxious mechanosensation was assessed by the pin-
prick test described previously (Arcourt et al., 2017). Mice were
housed and acclimatized similarly to the von Frey test. A pin-
prick stimulus was applied to the plantar surface of the hind
paw by a dissecting pin attached to a 1 g von Frey ﬁlament.
Latency to withdraw was recorded by a Sony Xperia phone at
120 fps (8.33ms per frame) and analysed by an investigator
blind to treatment groups. Three measurements were taken
for each hind paw per trial and averaged. Plotted latency rep-
resents the average of both paws. Baseline data represent the
average of two trials performed on separate days.
Motor performance was assessed by the rotarod performance
test (Ugo Basile, 47600). Mice were scored for their latency to
fall from a horizontal cylinder rotating at 32 rpm. Animals
were acclimatized to the equipment several days prior to testing
by placing them on the cylinder; ﬁrst while it was stationary
and then while rotating. Following acclimatization, two base-
line measurements were taken on separate days and averaged
to generate baseline data. Each data point represents one trial
performed on a given day. The Beam test (Carter et al., 2001)
apparatus consisted of a 1-m long horizontal beam of 12-mm
width suspended from the ground. Mice were placed at one end
of the beam next to a light source and walked across the beam
towards a darkened box. Trials were recorded once per
day and video footage was used by an investigator blind to
treatment groups, to assess number of mistakes (deﬁned
as missed hind paw placements or a hop). Mice were acclima-
tized to the apparatus prior to testing for 10min. Baseline
data were generated from the average of two trials on separate
days.
Thermal place preference was performed with the use of two
chambers with aluminium plates [in cm, 25 (w)  37 (d)  47
(h); Ugo Basile] as the base, connected by a short passage. One
plate was maintained at room temperature (22C) and the
other was set to 16C. Assigning temperatures to each plate
was performed at random to prevent animal learning. The
percentage time spent at each temperature was live-scored
over a 10-min period. Animals were acclimatized to the equip-
ment several days prior to testing by placing them on the
plates at room temperature for 10min. Following acclimatiza-
tion, two baseline measurements were performed on separate
days and averaged to generate baseline data.
Immunohistochemistry
For tissue collection, animals were deeply anaesthetized with
pentobarbital and perfused through the vascular system with
ice-cold 0.9% NaCl solution until tissues were sufﬁciently
cleared of blood. L4 DRGs, nodose ganglia, superior cervical
ganglia, lumbar sympathetic chain, hind paw glabrous skin
and peripheral nerves were collected and post-ﬁxed for 1–2 h
in 4% paraformaldehyde (PFA). Lumbar spinal cord and brain
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tissue were collected simultaneously and post-ﬁxed in 4% PFA
overnight. Post-ﬁxation, all tissue was stored in 30% sucrose
for a minimum of 48 h before being embedded and sectioned
by a cryostat. DRG, skin and nerve were sectioned at 15 mM,
while brain and spinal cord were sectioned at 30 mM.
Cell cultures were ﬁxed at room temperature for 10min
in 4% PFA and from there on treated similarly to tissue
sections.
Samples were incubated at room temperature for 1 h in
blocking solution (PBS + 0.3% TritonTM X-100 + 10%
normal goat serum), before overnight incubation with primary
antibody at 4C. Antibodies used in this study were as follows:
NeuN (1:500, rabbit, ab177487, Abcam), GFP (1:500, chicken,
ab13970, Abcam), NF200 (1:1000, rabbit, ABN76, Merck
Millipore), CGRP (1:1000, rabbit, T-4032.0050, Peninsula
Laboratories) IB4 (1:50, streptavidin conjugated, L2140,
Sigma-Aldrich), b-III-tubulin (1:500, rabbit, D71G9, Cell
Signalling), parvalbumin (1:200, guinea pig, Af1000, Frontier
Institute), PGP 9.5 (1:200, rabbit, 516-3344, Zytomed), ATF-3
(1:1000, rabbit, sc-81189, Santa Cruz) and BRN3A (1:100,
rabbit, Ab5945, Millipore). Samples were then incubated with
corresponding ﬂuorophore conjugated secondary antibodies
(1:1000, Alexa Fluor 488, 546 and 1:500 Paciﬁc Blue Dye,
Thermo Fischer Scientiﬁc), diluted in blocking solution for 2 h
at room temperature. Samples were mounted and viewed by a
Zeiss LSM-700 confocal microscope and ZEN software. Image
analysis was performed using Fuji/ImageJ (NIH). For image
quantiﬁcation, data were averaged from at least three sections
per tissue and sampled from at least three animals per group.
Only neurons with a clear nucleus were included in the analysis
of DRG cell size distribution.
Dorsal root ganglia neuron culture
and electroporation
DRG were rapidly excised (Sleigh et al., 2016) and enzymati-
cally digested at 37C for 80min in dispase type II (4.7mg/ml)
plus collagenase type II (4mg/ml) (Worthington Biochemical).
DRG from all levels were used except for experiments examin-
ing biophysical properties following SNI wherein only L3, L4
and L5 tissues were harvested. Mechanically dissociated cells
were plated onto laminin/poly-D-lysine (BD Biosciences) treated
coverslips in complete Neurobasal medium [Neurobasal
media supplemented with 2% (v/v) B27 and 1% (v/v) penicillin
streptomycin (ThermoFisher Scientiﬁc)]. Mouse nerve growth
factor (50 ng/ml; NGF, PeproTech) and 10ng/ml glial-derived
neurotrophic factor (GDNF, PeproTech) were added to
the media and cultures used for experiments 24–72h later.
For cultures generated from GluCl AAV animals, neurons
were plated and maintained in DMEM-F12 with 10% foetal
calf serum (ThermoFisher Scientiﬁc) instead of complete
Neurobasal medium and used for experiments 4–24h after
plating. Electroporation was performed prior to plating using
the Neon transfection system (ThermoFisher Scientiﬁc).
Dissociated neurons were resuspended at 5  106 cells/ml in
10ml Buffer R with 1mg of total plasmid DNA. The electrical
protocol applied was three 1500-V pulses of 10-ms duration.
After electroporation, cells were immediately plated as
described above and used 24–72h later, when expression of
the plasmid DNA was maximal.
Human embryonic kidney cell culture
HEK 293 cells were routinely subcultured in Dulbecco’s mod-
iﬁed Eagle medium (DMEM; ThermoFisher Scientiﬁc) with
10% foetal calf serum. Cells were plated in six-well dishes
24 h prior to transfection with LipofectamineTM 3000
(ThermoFisher Scientiﬁc) and plasmid DNA (total of 1 mg
DNA). Twenty-four hours post-transfection, cells were
replated onto coverslips at low density, before being used for
patch clamp experiments 24–48 h later.
Derivation of sensory neurons from
induced pluripotent stem cells
The control induced pluripotent stem cell (iPSC) line AD2-1
was derived from commercial ﬁbroblasts (Lonza, CC-2511)
and reprogrammed using the CytoTune iPS Reprogramming
Kit (ThermoFisher Scientiﬁc). Quality control checks of this line
included: tests for Sendai virus clearance, ﬂuorescence-activated
cell sorting (FACS) for pluripotency markers, genomic integrity
checks and embryoid body tri-lineage differentiation experi-
ments. For differentiation, iPSCs were passaged onto
Matrigel-coated six-well plates using TrypLE express
(ThermoFisher Scientiﬁc) and maintained in mTeSR1 supple-
mented with 10mM ROCK inhibitor (ScienCell). Twenty-four
hours after plating, the medium was exchanged to mouse em-
bryonic ﬁbroblast (MEF) conditioned medium (ScienCell)
supplemented with 10ng/ml human recombinant FGF2. Cells
were allowed to expand on MEF-conditioned medium until
50% conﬂuent, at which time differentiation was started
according to Chambers et al. (2012). Brieﬂy, medium was
exchanged to knockout serum replacement (KSR) medium con-
taining; knockout-DMEM, 15% knockout-serum replacement,
1% GlutaMAXTM, 1% non-essential amino acids, 100mM b-
mercaptoethanol, 1% antibiotic/antimycotic (ThermoFisher
Scientiﬁc), supplemented with the SMAD inhibitors SB431542
(Sigma, 10mM) and LDN-193189 (Stratech, 100nM). The
medium was gradually transitioned from KSR medium to N2
medium (Neurobasal medium, 2% B27 supplement, 1% N2
supplement, 1% GlutaMAXTM, 1% antibiotic/antimycotic)
(ThermoFisher Scientiﬁc) over an 11-day period. On Day 2,
the small molecules CHIR99021 (Apollo Scientiﬁc, 3mM),
SU5402 (R&D Systems, 10mM) and DAPT (Sigma, 10mM)
were also added. SMAD inhibitors were removed from the
media from Day 6 onwards. On Day 11, the now immature
neurons were replated onto Matrigel-coated coverslips
(25000 cells per 13mm coverslip) in 100% N2 medium con-
taining human recombinant NGF, GDNF, BDNF, NT3 (all at
25 ng/ml, PeproTech) and 10mM ROCK inhibitor. CHIR99021
(3mM) was included in the medium until Day 14, and laminin
(1mg/ml, ThermoFisher Scientiﬁc) was supplemented into the
medium from Day 20 onwards. Medium changes were per-
formed twice weekly after replating. Cytosine b-D-arabinofura-
noside (AraC, 2mM, Sigma) was included in the medium for
24h following replating to remove the few non-neuronal divid-
ing cells remaining in the culture. This differentiation resulted
in a pure neuronal culture with extensive arborized neurites by
2–3 weeks after the end of the small inhibitor stage. Neurons
were matured for 4 weeks before addition of AAV (GluClb-
YFP-AAV with or without GluCla-mCerulean-AAV) at a multi-
plicity of infection (MOI) of 105. All patch clamp and
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immunocytochemistry experiments were performed 1–3 weeks
post-virus treatment.
Electrophysiology
Whole-cell patch clamp recordings were performed at room tem-
perature (22C) using an Axopatch 200B ampliﬁer and Digidata
1550 acquisition system (Molecular Devices). GluCl+ DRGs
were deﬁned by the presence of YFP and detected with an
Olympus microscope with an inbuilt GFP ﬁlter set (470/40
excitation ﬁlter, dichroic LP 495 mirror and 525/50 emission
ﬁlter). Data were low-pass ﬁltered at 2kHz and sampled at
10kHz. Series resistance was compensated 60–80% to reduce
voltage errors. Patch pipettes of 2–6M tip resistance were
pulled from ﬁlamental borosilicate glass capillaries (1.5mm
outer diameter, 0.84mm inner diameter; World Precision
Instruments) and ﬁlled with internal solution containing (mM):
100K-gluconate, 28 KCl, 1 MgCl2, 5 MgATP, 10 HEPES, and
0.5 EGTA; pH was adjusted to 7.3 with KOH and osmolarity
set to 305 mOsm. For experiments of high intracellular Cl, KCl
was increased to 78mM while K-gluconate was reduced to
50mM. Extracellular solution contained (mM): 140 NaCl, 4.7
KCl, 1.2 MgCl2, 2.5 CaCl2, 10 HEPES and 10 glucose; pH was
adjusted to 7.3 with NaOH and osmolarity was set to 315
mOsm. Extracellular solution was perfused at a continuous
rate of 1–2ml/min. To assess voltage gated Na+ currents in
iPSC-sensory neurons, the internal solution contained (mM):
140 CsF, 10 NaCl, 1 EGTA and 10 HEPES. The extracellular
solution contained (mM): 70 NaCl, 50N-methyl-D-glucamine,
20 tetraethylammonium chloride, 1 CaCl2, 3 KCl, 1 MgCl2, 1
CaCl2, 10 HEPES, 10 glucose and 0.1 CdCl2. Ivermectin
(Sigma-Aldrich) was diluted to a 10000 stock in dimethyl
sulphoxide (DMSO) fresh daily and added via the perfusion
system. Unless otherwise stated, post-ivermectin recordings
were always made 15min after addition of the drug. In voltage
clamp, ramps from 90mV to 40mV were used to measure
membrane conductance. Ramps of 100ms duration were de-
livered in 10 s intervals and conductance was derived from the
linear portion of the resultant current slope. To assess voltage-
gated Na+ currents potential was stepped to 85mV for 8 s
before a 20ms test step to 0mV, from a holding potential of
100mV. Resting membrane potential was assessed in bridge
mode, while ﬁring properties were assessed in current clamp
mode. Input resistance (RInput) was derived from the membrane
potential deﬂection caused by a 20pA hyperpolarizing current
pulse at 60mV. To determine rheobase, cells were depolarized
from a holding potential of 60mV by depolarizing current
steps (50ms) of increasing magnitude (25pA) until an action
potential was generated. Spontaneous activity was deﬁned as the
presence of action potential ﬁring during a 1min bridge-mode
recording sweep made immediately upon establishing whole cell
access. Response to 10 s application of 1mM capsaicin was
assessed in bridge mode while recording from small diameter
(525mM) neurons.
Ca2+ imaging
For ratiometric Ca2+ imaging, cells were incubated with media
containing 2 mM Fura-2 AM and 80 mM pluronic acid
(ThermoFisher Scientiﬁc) for 1 h at 37C, before being
washed with extracellular ﬂuid (in mM, 145 NaCl, 5 KCl,
10 HEPES, 10 D-glucose, 2 CaCl2 and 1 MgCl2, pH 7.4).
For somal imaging, drug (vehicle or ivermectin) was added
during the Fura-2 AM and pluronic acid incubation step. A
10 objective, dichroic LP 409 mirror and BP 510/90 emitter
ﬁlter were used for Ca2+ imaging. Pairs of images using exci-
tation ﬁlters BP 340/30 and BP 387/15, respectively, were
captured every 2 s. Ratiometric 340/380 calculation was per-
formed with a background subtraction. GluCl+ DRG were
identiﬁed using BP 480/30 excitation ﬁlter, dichroic LP 505
mirror and BP 535/40 emission ﬁlter and labelled as such
prior to recording protocols. Extracellular ﬂuid was perfused
with the addition of drugs by a gravity-driven application
system with remotely controlled pinch valves. Therefore, the
entire stimulation protocol and ivermectin application was per-
formed in a time-locked and hands-free manner. Cells exhibit-
ing a time-locked Ca2+ transient 40.2 F/F were deﬁned as
having responded.
Compartmentalized microﬂuidic chambers were composed of
a polydimethylsiloxane (PDMS) piece in which a pattern of
channels and microgrooves were moulded that was bonded to
a glass bottom culture dish. The fabrication of the master tem-
plate in which the PDMS pieces were moulded from was per-
formed as previously described in detail (Park et al., 2006).
Embryonic Day 16 rat DRG were processed for culture simi-
larly to adult mouse tissue but with a reduced enzymatic diges-
tion step of 45min. We used rat DRG for this experiment as in
our hands they grow through the microgrooves better and
more consistently generate somal responses to terminal stimu-
lation. Once dissociated embryonic rat DRG were resuspended
in complete Neurobasal medium and 10000 cells were plated
in a 4ml volume in only one compartment using capillary
action to draw the cell suspension along the entire compart-
ment length. Ten microlitres of complete Neurobasal medium
was placed in the adjacent compartment. Cells were left to
adhere for a minimum of 2 h before ﬂooding the channels
with complete Neurobasal medium. To encourage axonal
growth through the microgrooves we exploited the ﬂuidic re-
sistance to create a unidirectional NGF/GDNF gradient across
the array. This was established according to Table 1.
DRG neurons were treated with AAV (GluClb-AAV with or
without GluCla-AAV) 3 days post-plating at an MOI of 100.
Imaging experiments were performed 7 days post-plating.
To identify neurons that had grown a neurite through the
Table 1 Chemoattraction protocol
Somal compartment Neurite compartment
Day 0 50 ng/ml NGF, 10 ng/ml GDNF in 200ml 50 ng/ml NGF, 10 ng/ml GDNF in 200ml
Day 1 5 ng/ml NGF, 1 ng/ml GDNF in 160ml 50 ng/ml NGF, 10 ng/ml GDNF in 200ml
Day 2 0 ng/ml NGF, 0 ng/ml GDNF in 160ml 50 ng/ml NGF, 10 ng/ml GDNF in 200ml
Days 3 and 5 0 ng/ml NGF, 0 ng/ml GDNF in 160ml 50 ng/ml NGF, 10 ng/ml GDNF in 200ml
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microgroove array, 100ml of 1,1’-dioctadecyl-3,3,3’,3’-tetra-
methylindocarbocyanine perchlorate (DiI, Invitrogen, 40mg/ml
in complete Neurobasal medium) was applied to the axonal
compartment 2h prior to Ca2+ imaging, with 200ml of medium
in the somal compartment to maintain ﬂuidic isolation. Neurons
that were positive for DiI and GluCl subunits (GluCla and
GluClb, or GluClb only) were identiﬁed and subsequently
used to assess Ca2+ response. Averages from one litter were
used to compute group means and measures of group variance.
Statistical comparisons were always made on the basis of litter
number.
Statistical analysis
Data are expressed throughout as mean  standard error of
the mean (SEM). Student’s t-test was used to compare the
mean of two samples and one-way ANOVA for multiple
comparisons. Where data related to pre- and post-ivermectin,
a paired t-test was performed. Proportion of cells in excitable
states was assessed by chi-squared test and the presence of
spontaneous activity by Fischer’s exact t-test. For behavioural
experiments over time, repeated measures ANOVA was used
followed by post hoc Bonferroni test. Normality was assessed
by Shapiro–Wilk test and non-parametric tests were used
when appropriate (Wilcoxon signed-rank and Kruskal–
Wallis tests). Statistical testing was performed with Excel or
GraphPad Prism. P50.05 was taken as our threshold for
signiﬁcance.
Results
Evoked firing of sensory neurons is
silenced by GluCl activation
To assess the efﬁcacy of GluCl for silencing sensory neu-
rons, we ﬁrst performed whole-cell patch clamp recordings
of dissociated mouse DRG neurons electroporated with
GluCl plasmid DNA. At rest, neurons expressing both a-
and b-subunits of GluCl (Fig. 1A) had similar membrane
and ﬁring properties to control (neurons electroporated
with GFP-only vector) (Supplementary Table 1), suggestive
of no GluCl activity. However, low levels of ivermectin
induced a slow, stable and dose-dependent conductance
(Fig. 1B and C). Neurons expressing only the b-subunit
of GluCl did not respond to ivermectin, consistent with
previous observations that this subunit does not form func-
tional ivermectin-sensitive homomers (Frazier et al., 2013).
This validated our use of GluCl b-only as a suitable control
in future experiments. Unlike CNS neurons, sensory neu-
rons maintain a high intracellular Cl concentration
([Cl]i) (Gilbert et al., 2007) and as such, initiating a Cl

conductance would not be expected to inhibit activity by
the classical fashion of hyperpolarizing the membrane po-
tential (Vm). We reasoned, however, that the large drop in
membrane resistance associated with GluCl activation
(Fig. 1D) would be sufﬁcient to inhibit neuronal activity.
Indeed under our recording conditions ([Cl]i = 30mM)
GluCl activation potently reduced evoked ﬁring. After
15min treatment with 20 nM ivermectin, 95.83% (23/24)
of GluCl+ neurons did not generate an action potential in
response to a current stimulus 10-fold the pre-ivermectin
rheobase value, while control neurons were unaffected
(Fig. 1E and F). The transient opening of Cl channels
can depolarize and activate sensory neurons (Cho et al.,
2012). However, we noted no action potential ﬁring in
the 15min prelude to assessment of evoked ﬁring in
GluCl+ neurons (5 nM ivermectin n = 13 cells, 20 nM iver-
mectin n = 13). Cells recorded from ranged in diameter
from 15 to 40 mm and silencing was effective in all sizes
of neuron (Supplementary Fig. 1). DRG [Cl]i levels are
heterogeneous (Gilbert et al., 2007) and can be increased
after nerve injury (Pieraut et al., 2007), altering the polarity
and drive of Cl ﬂux. Under recording conditions of high
intracellular Cl ([Cl]i = 80mM, ECl = 16mV) ivermec-
tin depolarized Vm, but was still effective at silencing neur-
onal activity (Fig. 1G and Supplementary Fig. 2). These
results indicate that even when providing a depolarizing
drive, GluCl activity can silence evoked electrical activity
of sensory neurons.
GluCl silencing is effective at the axon
as well as the soma
To circumvent confounds of whole-cell patching and artiﬁ-
cial modulation of intracellular ionic concentrations; we per-
formed Ca2+ -imaging experiments. The proportion of
GluCl+ neurons responding to KCl-induced depolarization
and naturally occurring TRP channel agonists [menthol
(McKemy et al., 2002) and capsaicin (Caterina et al.,
1997)] following ivermectin was markedly reduced
compared to control, indicative of effective silencing
(Fig. 2A). The fact that the Ca2+ response to capsaicin
was not completely abolished likely represents the direct
entry of Ca2+ through TRPV1 (a non-selective cation chan-
nel). This notion is supported by our ﬁnding that GluCl+
neurons did not ﬁre action potentials in response to capsa-
icin, following 20nM ivermectin (Supplementary Fig. 3).
Whether GluCl activation silences neurons solely at the
level of the soma or also blocks axonal action potential
propagation has not previously been determined; but the
question is highly relevant to sensory neurons given their
long axonal projections. We used microﬂuidic compartments
to separate the soma and neurites of GluCl+ neurons (Fig.
2B) (Park et al., 2006). Local depolarization of neurites leads
to Ca2+ transients in DRG cell bodies dependent on axonal
transmission (Fig. 2C). Ivermectin applied only to neurite
endings was able to almost entirely block soma responses
to neurite depolarization (Fig. 2D and E), suggesting that
GluCl activation can interfere with primary afferent trans-
mission at the level of the axon and not just the soma. The
in vitro data illustrate that GluCl activation can potently
silence sensory neurons and compelled us to assess whether
the system was applicable to the in vivo setting.
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Intrathecal AAV effectively delivers
GluCl to sensory neurons in vivo
Following nerve injury, evidence exists that both myelinated
(Wall and Gutnick, 1974; Wall and Devor, 1983; Kajander
and Bennett, 1992) and unmyelinated afferents (Wu et al.,
2001; Serra et al., 2012) are involved in the generation of
neuropathic pain (Ossipov et al., 1999; Tarpley et al., 2004;
Xu et al., 2015). We therefore aimed to deliver GluCl to a
broad range of sensory neurons in vivo. We engineered
AAV9 to express GluCla and GluClb separately; under
the control of the ubiquitous CAG promoter and modiﬁed
GluCla to contain a monomeric cerulean ﬂuorophore in the
place of YFP to better visualize subunit co-localization
(Supplementary Fig. 4). Fluorophore switch had no effect
on channel function (Supplementary Fig. 4). We used intra-
thecal delivery to selectively transduce neurons of the
sensory ganglia while avoiding transduction of spinal cord
neurons (Mason et al., 2010; Jacques et al., 2012). Four
weeks post-surgery, GluCl was expressed in 66.1  9.6%
of L4 DRG neurons (n = 4 animals with one excluded
from analysis due to zero expression) (Fig. 3A). Size fre-
quency analysis of GluCl+ neurons revealed equally distrib-
uted transduction of neurons across all diameters (Fig. 3B).
Consistent with this result, co-labelling experiments showed
that transduction rates were similar across different molecu-
larly deﬁned sub-populations (Fig. 3C and D) and was not
selective for a particular population. Homomeric GluCl
channels provide little or no conductance in response to
ivermectin (Frazier et al., 2013); however, we found that
the vast majority (78.9%) of GluCl+ neurons expressed
both subunits (Supplementary Fig. 5). GluCl+ afferent end-
ings were seen in superﬁcial and deep dorsal horn laminae
but crucially no expression was seen in ventral horn
Figure 1 GluCl activation silences electrical activity of DRG neurons in vitro. Whole-cell patch clamp recordings of DRG neurons
electroporated with GluCla/b-YFP. (A) GluCl + DRG neuron. Scale bar = 30mm. (B) Voltage ramp used to determine membrane conductance.
Ivermectin (IVM, 20 nM) treatment induces a membrane conductance in GluCl + DRG, as seen by the increased slope of the current trace.
(C) Induced conductance in response to ivermectin. (Inset) Example recording of ivermectin-conductance over time. One-way ANOVA with post
hoc Bonferroni test comparing groups to control (GFP), GFP 5 nM ivermectin n = 10, GFP 20 nM ivermectin n = 10, b-only 5 nM ivermectin n = 11,
b-only 20 nM ivermectin n = 15, ab 5 nM ivermectin n = 24 and ab 20 nM ivermectin n = 24. (D) Change in input resistance following ivermectin.
One-way ANOVA with post hoc Bonferroni test comparing groups to control (GFP), GFP 5 nM ivermectin n = 10, GFP 20 nM ivermectin n = 10,
b-only 5 nM ivermectin n = 11, b-only 20 nM ivermectin n = 15, ab 5 nM ivermectin n = 24 and ab 20 nM ivermectin n = 24. (E) Firing of neurons
in response to supra-threshold current injection pre- and post-ivermectin treatment. (F) Ability of GluCl + neurons to fire an action potential in
response to a short (50 ms) depolarizing current. Neuronal excitability was defined by the fold-increase in rheobase comparing pre- and post-
ivermectin values: 53 (excitable), 3–10 (partial silencing) or 410-fold (full silencing). P5 0.001, chi-squared test (2 = 55.74 with 4 degrees
of freedom). b-only 5 nM ivermectin n = 11, b-only 20 nM ivermectin n = 15, ab 5 nM ivermectin n = 24 and ab 20 nM ivermectin n = 24.
(G) Excitability of GluCl + DRG assessed while using an intracellular solution containing 80 mM Cl. (Left) Example firing of a GluCl + neuron in
response to supra-threshold current stimuli pre- and post-ivermectin (20 nM). (Right) Following ivermectin, 5/5 neurons were unable to fire
an action potential in response to a current 10-fold their pre-drug rheobase value (full silencing). All grouped data are mean  SEM, *P5 0.05,
**P5 0.01, ***P5 0.001; P5 0.0001.
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motor neurons (Fig. 3E), brain or autonomic structures
(Supplementary Fig. 6). In the periphery we observed
GluCl expression in neurite endings of the skin and deep
dermal nerve ﬁbres (Supplementary Fig. 7). Channel activity
remains for several days post-ivermectin dosing due to slow
dissociation from the channel (Slimko et al., 2002) and
tissue retention of ivermectin (Lerchner et al., 2007). This
allowed us to test silencing efﬁcacy following AAV delivery
and agonist treatment in vivo. GluCl-AAV animals were
dosed with 5mg/kg ivermectin i.p. 24h prior to dissociation
of lumbar DRG. Ex vivo GluCl+ DRG neurons exhibited
analogous features to those observed in vitro; a substantive
basal conductance and an inability to generate action po-
tentials in response to current injection (Fig. 3F and G).
Neurons did not exhibit a signiﬁcantly different resting
membrane potential (b-only naı¨ve, 59.39  2.23mV
versus ab ivermectin, 56.01  1.9, P = 0.18 Student’s
t-test.) AAV is considered a suitable vehicle to achieve
long-term expression of exogenous transgenes in target
tissue (Hadaczek et al., 2010), which makes it a highly
attractive approach from a translational perspective.
However, there are previous reports of partial shutdown
of transgene expression over time when AAV is used to
target DRG (Mason et al., 2010; Iyer et al., 2014). To
assess expression longevity, we maintained a small cohort
of GluCl-AAV animals for 7 months and found robust
expression still evident (Supplementary Fig. 8). We noted
no reduction in cutaneous afferent innervation or upregula-
tion of the injury marker ATF3 (Supplementary Fig. 9).
In vivo silencing elevates mechanical
and thermal pain thresholds
To determine whether GluCl activation was sufﬁcient to alter
sensory thresholds, we performed tests of reﬂex withdrawal
to mechanical (von Frey), thermal (Hargreaves) and noxious
mechanical (pinprick) stimuli. Twenty-four hours post-iver-
mectin treatment mechanical thresholds of GluCl+ animals
were increased by 63.04  20.86% (P = 0.015) (Fig. 4A),
thermal thresholds were increased by 48.4  15.62%
(P = 0.007) (Fig. 4B) and latency to withdraw from a noxious
Figure 2 GluCl mediates local silencing in response to excitatory stimuli. (A, left) Representative somal Ca2 + responses of
ivermectin-treated DRG neurons to consecutive stimulation with 200mM menthol (Men), 1 mM capsaicin (Cap) and 50 mM KCl. (Right)
Proportion of neurons that responded to each stimuli. One-way ANOVA with post hoc Bonferroni test. Data derived from n = 9 independent
experiments (GluCl + , total of 162 neurons, GluCl, 629 neurons). (B) Schematic of experimental set-up illustrating somal and neurite com-
partments separated by a microgroove array. DiI treatment of the neurite compartment marks GluCl + cell bodies that have successfully sent
axonal projections through the microgroove array. GluCl + axons are clearly discernable in the neurite compartment. Scale bars = 50 mm.
(C) Somal Ca2 + transients of a control neuron in response to the experimental stimulation protocol [two KCl (50 mM) neurite stimulations
separated by 12 min ivermectin (20 nM) wash-on only to the neurite compartment]. This set-up allows us to assess the effect of local drug
administration to axonal activation. (D) Ratiometric Ca2 + responses of DRG cell bodies while neurites are stimulated in isolated compartments,
before and after acute ivermectin treatment of neurites. (E) Percentage of cell bodies that responded to the second neurite depolarization
stimulus, as a proportion of those that responded to the first stimulation. Student’s unpaired t-test, n = 4 independent experiments (b-only, total
of 138 cells, ab, 200 cells). All grouped data are mean  SEM, *P5 0.05, **P5 0.01, ***P5 0.001.
Chemogenetic treatment of neuropathic pain BRAIN 2017: 140; 2570–2585 | 2577
D
ow
nloaded from
 https://academ
ic.oup.com
/brain/article-abstract/140/10/2570/4085760 by U
niversity of G
lasgow
 user on 25 N
ovem
ber 2019
Figure 3 Intrathecal delivery of GluCl-AAV efficiently transduces sensory neurons. Analysis of tissue taken from animals 4 weeks
following intrathecal co-delivery of AAV9-GluCla and AAV9-GluClb. (A, left) L4 DRG immunostained for YFP (green) and NeuN (red). Scale
bar = 100mm. (Right) GluCl+ DRG as a proportion of total neurons. Data represent mean  SEM from three animals and a total of 912 neurons.
(B) Size distribution of GluCl+ neurons. Data pooled from three animals and represent a total of 379 cells. (C) GluCl (green) co-localization with
DRG subpopulation markers (magenta). White arrows show double-labelled neurons. Scale bar = 30mm. (D) Percentage of GluCl+ DRG in the
different subpopulations. Data represent results from n = 3 animals and a total of 4600 cells/group. (E) Representative lumbar spinal cord
immunostained for YFP (n = 4 animals assessed). Scale bar = 100mm. (F) Membrane conductance of ex vivo GluCl+ neurons taken from GluCl-AAV
animals untreated (Naı¨ve) and 24 h following 5 mg/kg i.p. ivermectin (IVM). (Left) Current traces in response to membrane voltage ramp 90 to
40 mV (0.5 mV/ms) of neurons from ivermectin treated animals. (Right) Quantification of membrane conductance. One-way ANOVA followed by
post hoc Bonferroni test comparing groups to control (Naive b-only), naive b-only, n = 8; naı¨ve ab, n = 7; ivermectin b-only, n = 8; ivermectin ab,
n = 10. (G) Firing properties of GluCl-AAV animal derived GluCl+ neurons. (Left) Action potential traces in response to depolarizing current
injection of DRG neurons derived from ivermectin-treated animals. (Right) Excitability status as defined by a rheobase value: 53 (excitable), 3–10
(partial silencing) or 410 (full silencing) standard deviations above the mean of control (Naı¨ve b-only, mean = 160.1  160.6 pA). P5 0.001,
chi-squared test (2 = 32.52 with 6 degrees of freedom); Naive b-only, n = 8; Naı¨ve ab, n = 7; ivermectin b-only, n = 8; ivermectin ab, n = 10. All
averaged data represent the mean  SEM. ***P5 0.001.
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mechanical stimulus by 62.2  8.3% (P = 0.034) (Fig. 4C).
Motor performance and proprioception (as assessed by the
rotarod and beam walk tests, respectively) were not affected
in either experimental or control groups following ivermectin
(Fig. 4D and E). We investigated in detail the time course of
GluCl-mediated behavioural responses. After a single dose,
hypo-responsiveness was apparent by 24h and was main-
tained for 3 days before thresholds returned to baseline by
6 days (Fig. 4F). Once GluCl channels have closed following
ivermectin washout they should be amenable to reactivation
by a subsequent dose of the drug (Lerchner et al., 2007).
Indeed, we found that a second ivermectin administration
had similar efﬁcacy to the ﬁrst after an interval of 3 weeks
(Fig. 4G). These results highlight GluCl silencing of DRG
neurons as a means to non-invasively manipulate sensory
thresholds in a chronic and reproducible fashion.
GluCl activation reverses traumatic
nerve injury-induced hypersensitivity
Chronic pain following nerve injury is driven by hyperexcit-
ability (Smith et al., 2013) and ectopic activity of primary
afferents (Haroutounian et al., 2014; Vaso et al., 2014). We
asked whether our approach of long-term electrical silencing
of afferents would be sufﬁcient to counter this phenomenon
in animals that had undergone SNI (Decosterd and Woolf,
2000). We found that GluCl activation could repetitively
reverse established mechanical hypersensitivity following
SNI (Fig. 5A and Supplementary Fig. 10). Post hoc tissue
analysis revealed that the degree of rescue correlated well
with the proportion of L4 DRG cells expressing GluCl
(Fig. 5B), supporting the view that primary afferent drive
is critical for the maintenance of the neuropathic pain
state. We used a two-chamber cold place preference as an
operant measure of thermal hypersensitivity following nerve
injury (Balayssac et al., 2014). One week after SNI, animals
spend signiﬁcantly less time in the cold (16C chamber
versus 22C) than pre-injury levels. Ivermectin reversed the
observed cold allodynia in the experimental group but had
no effect on controls (Fig. 5C). As a cellular correlate,
we studied DRG neurons taken from chronic SNI animals
(25–33 days post-SNI) for their electrophysiological proper-
ties in vitro. Ex vivo neurons derived from injured DRG had
a higher incidence of ectopic activity than control [ipsilateral
Figure 4 GluCl activation increases thermal and mechanical pain thresholds. (A) Von Frey test of mechanical sensitivity (b only,
n = 14 animals and ab, n = 13); (B) Hargreaves test of thermal sensitivity (b only, n = 14 animals and ab, n = 13); (C) Pinprick assay of noxious
mechanosensation (b only, n = 11 animals and ab, n = 10); (D) Rotarod test of motor performance (b only, n = 14 animals and ab, n = 13); and
(E) beam walk test of proprioception (b only, n = 8 animals and ab, n = 9) of GluCl AAV animals before and 24 h following 5 mg/kg ivermectin
(IVM). Student’s paired t-test. (F) Time course of thermal sensitivity following a single dose of systemic ivermectin. Repeated measures ANOVA
followed by post hoc Bonferroni test comparing b only (n = 12) and ab (n = 10.) (E) Ivermectin-induced change in thermal sensitivity of two
separate doses of ivermectin given 24 h prior to testing, performed 3 weeks apart. Student’s paired t-test, n = 6 animals. All averaged data
represent mean  SEM. *P5 0.05, **P5 0.01. BS = baseline.
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(8/24 cells) versus contralateral (1/20 cells), P = 0.027
Fischer’s exact t-test]. However, injured neurons from iver-
mectin-treated GluCl+ animals exhibited no ectopic activity
(Fig. 5D) and largely silenced evoked activity (Table 2), in-
dicative of robust silencing. GluCl activation is therefore suf-
ﬁcient to silence nerve-injury induced ectopic activity of
primary afferents and reverse pain related behaviour.
GluCl silences human iPSC-derived
sensory neurons
The use of human model systems can potentially improve
translation of preclinical ﬁndings in animal models into
clinical therapeutics (Woolf, 2010; Percie Du Sert and
Rice, 2014). To address whether the GluCl system may
have efﬁcacy in the context of human sensory neurons,
we generated cultures of human iPSC-derived sensory neu-
rons. We followed a differentiation protocol known to pro-
duce neurons with an expression proﬁle and functional
characteristics that are very similar to rodent sensory
neurons (Chambers et al., 2012; Young et al., 2014;
Clark et al., 2017). Resultant neurons uniformly express
the sensory neuron marker Brn3a, project extensively
arborized neurites and exhibit mature electrophysiological
characteristics (Fig. 6A–C). Analogous to mouse DRG,
human iPSC-sensory neurons expressing GluCl and treated
with ivermectin show a substantial conductance (Fig. 6D–
F) and limited capacity to generate action potentials to
otherwise suprathreshold current stimuli (Fig. 6G and H).
These results indicate the generality of the GluCl system
and its potential relevance for use in human sensory
neurons.
Discussion
To summarize, we show that activation of GluCl channels
results in robust silencing of rodent and human iPSC-
derived sensory neurons. AAV-mediated delivery is capable
of highly speciﬁc, efﬁcient and long-lasting expression of
Figure 5 GluCl activation can reverse nerve injury-induced hypersensitivity. (A) Time course of mechanical hypersensitivity following
SNI. Red arrows indicate the time at which animals received a systemic dose of 5 mg/kg ivermectin. *P5 0.05, repeated measures (RM)-ANOVA
followed by post hoc Bonferroni test comparing means of b-only and ab groups. #P5 0.05, repeated measures ANOVA followed by post hoc
Bonferroni test comparing post-SNI time-points with Day 7, n = 11 animals per group. (B) Correlation between average rescue (Days 8 and 15) of
mechanical hypersensitivity following a single dose of ivermectin and the proportion of L4 DRG neurons expressing GluCl. *P5 0.05, Pearson’s
correlation co-efficient. (C) Time spent at 16C versus 22C drops 7 days after SNI but is recovered 24 h following systemic ivermectin.
**P5 0.01, *P5 0.05, repeated measures ANOVA followed by post hoc Bonferroni test comparing means of b-only and ab groups. #P5 0.05,
repeated measures ANOVA followed by post hoc Bonferroni test comparing means at Day 7 versus Day 8, n = 11 animals per group. (D, left)
traces of GluCl + neurons taken from uninjured (contralateral) and injured (ipsilateral) DRG of SNI animals illustrating resting membrane potential
over 30 s. (Right) Proportion of cells exhibiting ectopic activity. **P5 0.01, chi-squared test (2 = 12.01 with 2 degrees of freedom), data derived
from three independent experiments. All averaged data represent mean  SEM. SA = spontaneous activity.
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GluCl in sensory neurons in vivo without deﬁcits in cuta-
neous afferent innervation or upregulation of the injury
marker ATF3 and can normalize pain-related behaviour
following peripheral nerve injury in a reproducible and re-
versible fashion.
The GluCl channel that we used in this study is a hetero-
meric glutamate-gated chloride channel modiﬁed so be
activated by low doses of ivermectin, but is insensitive to
its natural ligand glutamate (Slimko et al., 2002). The ini-
tial version (GluCl v1.0) has previously been used to silence
neurons in the CNS (Lerchner et al., 2007; Lin et al.,
2011). In this study we used a recently modiﬁed version
(GluCl v2.0), which shows higher sensitivity to ivermectin
and improved trafﬁcking of the b-subunit (Frazier et al.,
Table 2 Biophysical and firing properties of DRG neurons from SNI animals
b only ab
Contralateral Ipsilateral P-value Ipsilateral P-value
Resting membrane potential (mV) 57.15  1.46 56.68  1.79 40.99 51.17  2.24 0.08
Input resistance (M) 193.33  20.44 183.33  22.76 40.99 75.97  7.95*** 50.001
Rheobase (pA) 146.31  15.15 181.21  32.69 40.99 1476.22  313.79*** 50.001
Capacitance (pF) 31.49  1.84 32.53  2.30 40.99 31.3  2.76 40.99
Number of cells 20 24 21
***P5 0.001, one-way ANOVA comparing group versus control (b-only contralateral), followed by post hoc Bonferroni test. Only ab neurons that fired an action potential
contributed to rheobase values (12/21 cells).
Figure 6 GluCl activation silences human iPSC-derived sensory neurons. (A) Mature human iPSC-derived sensory neurons stain
positive for the sensory neuron transcription factor Brn3a (green) and neuronal marker b-III tubulin (magenta). Scale bar = 50 mm. (B) Evoked
firing in response to short (left) and long (right) depolarizing current injection. Note the inflection on the falling phase of the action potential—a
property of endogenous nociceptors. (C) Example voltage clamp recording demonstrating both a TTX-sensitive and a TTX-resistant component
to the Na + current evoked by membrane depolarization to 0 mV. (D) GluCl expression in human iPSC-sensory neurons 2 weeks following
treatment with GluCl-AAV. Scale bar = 50 mm. (E) Voltage ramp recordings of neurons expressing GluCl and treated with ivermectin (IVM,
20 nM). (F) Quantification of membrane conductance of neurons pretreated with either ivermectin (20 nM) or vehicle (0.01% DMSO). Kruskal-
Wallis followed by post hoc Dunn’s test comparing groups to control (vehicle treated b-only): vehicle b-only, n = 9; vehicle ab, n = 11; ivermectin
b-only, n = 11; and ivermectin ab, n = 13. (G) Evoked firing in response to supra-threshold current injection pre- and post-ivermectin treatment.
(H) Neuronal excitability as defined based on a rheobase value; 53 (excitable), 3–10 (partial silencing) or 410 (full silencing) standard deviations
above the mean of control (vehicle treated b-only, mean = 103  28.2 pA). P5 0.001, chi-squared test (2 = 32.45 with 6 degrees of freedom);
vehicle b-only, n = 9; vehicle ab, n = 11; ivermectin b-only, n = 11; and ivermectin ab n = 13. All grouped data are mean  SEM, ***P5 0.001.
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2013), but has (up until now) not been tested in vivo or in
the peripheral nervous system. We were struck by the efﬁ-
cacy of GluCl v2.0 in silencing rodent sensory neurons
both in vitro and ex vivo. In the absence of ligand, neurons
expressing GluCl were electrically normal, but treatment
with low levels of ivermectin evoked a substantive mem-
brane conductance that rendered almost all neurons
entirely resistant to evoked ﬁring.
Systems designed to inhibit neuronal activity are classically
designed to hyperpolarize the membrane potential (Lechner
et al., 2002; Slimko et al., 2002; Armbruster et al., 2007) and
render the cell less likely to reach ﬁring threshold. In CNS
neurons, Cl has a hyperpolarized Nernst potential due to
low [Cl]i levels and therefore an increased conductance will
hyperpolarize the resting membrane potential (Lerchner et al.,
2007). DRG neurons are unique in that they actively main-
tain higher [Cl]i through activity of several Cl
 co-trans-
porters (Sung et al., 2000). Consistent with this we found
that GluCl activation did not hyperpolarize the membrane
potential; however, we still noted substantial silencing
efﬁcacy. This may be explained by the marked reduction in
membrane resistance associated with GluCl activation, resem-
bling the phenomena of shunting inhibition observed in
endogenous neural systems (Segev, 1990; Borg-Graham
et al., 1998). Despite this, the precise mechanism of silencing
would prove challenging to demonstrate empirically.
Ca2+ inﬂux to the soma in response to natural stimuli
[menthol and capsaicin, which activate subsets of small
diameter DRG cells (Caterina et al., 1997; McKemy
et al., 2002)] was reduced in GluCl-activated neurons.
Given the long pseudo-unipolar axons of sensory neurons,
there are advantages to a silencing system that can act on
neurites as well as at the level of the soma. Using a micro-
ﬂuidic platform in which soma and neurites can be isolated
and treated independently, we show that ivermectin appli-
cation to sensory neurites alone is sufﬁcient to prevent
action potential propagation to the soma following periph-
eral depolarization.
With a view to translational applications and to test
whether there were cross-species differences in silencing
efﬁcacy, we investigated whether the GluCl system could
silence human iPSC-derived sensory neurons. We used a
previously published differentiation protocol known to
generate sensory neurons (Chambers et al., 2012) that
has been shown to be a valuable model of human pain
disorders (Young et al., 2014; Cao et al., 2016).
Ivermectin treatment of human iPSC-derived sensory neu-
rons expressing GluCl evokes a membrane conductance
and silences these neurons to a similar extent as their
rodent analogues.
Ivermectin does not readily cross the blood–brain barrier
(Schinkel et al., 1994), leading previous studies of the
GluCl system in the CNS to use relatively high dosing re-
gimes (Lerchner et al., 2007). When administering ivermec-
tin in vivo we opted to use the lower end of the dose range
(5mg/kg) as our target was peripheral neurons. This lower
dose reduces the likelihood of off-target effects given that at
high doses ivermectin can bind to GABAA receptors
(Dawson et al., 2000). Doses of ivermectin 510mg/kg
have been shown not to have CNS depressant effects
(Trailovic and Nedeljkovic, 2011). Reassuringly we did
not observe any effects of ivermectin at a dose of 5mg/kg
on sensory or motor function in control animals (either in
the naı¨ve state or following nerve injury). In experimental
animals expressing GluCl, a single dose of ivermectin re-
sulted in a signiﬁcant elevation of reﬂex withdrawal thresh-
olds to noxious mechanical and thermal stimuli lasting
3 days. This is similar to the long-lasting behavioural ef-
fects previously observed following use of the GluCl v1.0
system in the striatum (Lerchner et al., 2007) and is
thought to possibly reﬂect slow dissociation of ivermectin
from GluCl (Slimko et al., 2002) and/or long-lasting reten-
tion of ivermectin in tissue (Lerchner et al., 2007).
Importantly we noted that not only were the effects revers-
ible but could also be reproduced following a subsequent
treatment. We did not observe any motor deﬁcits.
Finally, we tested the efﬁcacy of GluCl in the spared
nerve injury model of neuropathic pain (Decosterd and
Woolf, 2000). Importantly, we treated with ivermectin at
1 week post-injury, a time when mechanical and cold
hypersensitivity is well established. Ivermectin could signiﬁ-
cantly ameliorate mechanical pain-related hypersensitivity
as well as reversing cold allodynia. This effect was revers-
ible and reproducible up to 3 weeks post-injury, which was
the last time point of testing. There was a signiﬁcant cor-
relation between the proportion of DRG cells transduced
with GluCl and the degree of reversal of mechanical pain-
related hypersensitivity. Consistent with these behavioural
ﬁndings, we found that when assessed ex vivo ivermectin
had successfully suppressed both ectopic and evoked activ-
ity in those sensory neurons expressing GluCl. Given the
selectivity of AAV delivery for sensory neurons these ﬁnd-
ings emphasize the importance of aberrant primary afferent
input in the maintenance of neuropathic pain (Vaso et al.,
2014). The past decade has seen exciting developments in
the identiﬁcation of ion channels/signalling pathways con-
tributing to the development and maintenance of neuro-
pathic pain (Waxman and Zamponi, 2014; Habib et al.,
2015). A caveat to therapeutically targeting individual mol-
ecules is the proposed degeneracy in the development of
neuronal hyperexcitability following nerve injury (Ratte
et al., 2014). GluCl activation represents a strategy to cir-
cumvent this problem by silencing neuronal activity regard-
less of inherent dysregulation in the system. This property
may make the system also appropriate for other neuro-
logical disorders whereby dampening of neuronal excitabil-
ity could prove efﬁcacious, such as epilepsy (Avaliani et al.,
2016).
This is the ﬁrst demonstration of efﬁcacy of a chemoge-
netic system in a chronic pain model. There is some evi-
dence that expression of the designer inhibitory G-protein-
coupled receptor hM4Di (inhibitory designer receptor
exclusively activated by designer drug DREADD)
(Armbruster et al., 2007) in primary afferents can alter
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acute pain thresholds in vivo (Iyer et al., 2016; Saloman
et al., 2016), however although widely used in the CNS its
applicability to peripheral sensory neurons is questionable.
Mouse sensory neurons do not exhibit functional GIRK
currents (Nockemann et al., 2013), thought to be the en-
dogenous mediator of hM4Di silencing (Armbruster et al.,
2007). This contrasts with rat and human sensory neurons
wherein at least a proportion of sensory neurons do express
GIRK channels (Nockemann et al., 2013). In recordings
from mouse DRG cells expressing hM4Di the reported ef-
ﬁcacy was limited with 550% of such neurons showing a
change in excitability (Saloman et al., 2016). These authors
have also shown that hM4Di expression in primary affer-
ents alters Na+ and Ca2+ currents in the absence of
the ligand (Clozapine-N-oxide, CNO) and inhibits the an-
algesic effect of endogenous inhibitory G-protein-coupled
receptors (a major confound if this were ever to be used
therapeutically). Finally there are also concerns about the
safety of the receptor ligand, CNO (Jann et al., 1994;
Chang et al., 1998; Maclaren et al., 2016).
Other forms of neuromodulation include electrical stimu-
lation devices (Colloca et al., 2017) and optogenetics (which
has not yet been applied to patients). Optogenetics offers
exciting opportunities but also faces many challenges, lar-
gely based on safely delivering sufﬁcient illumination to
target tissues (Montgomery et al., 2016). The chemogenetic
approach has potential advantages, for instance in the abil-
ity to silence deep afferents inaccessible to light, which are a
key source of ectopic activity (Michaelis et al., 2000;
Kirillova et al., 2011), without the need of implants. One
disadvantage is that ivermectin-mediated silencing in vivo
exhibits temporal imprecision; however, the fact that behav-
ioural efﬁcacy is maintained for 3 days following a single
dose could be advantageous when treating disorders of per-
sistent hyperexcitability such as neuropathic pain.
Neuromodulation mediated by electrical stimulation is
used in the treatment of neuropathic pain (Kumar and
Rizvi, 2014). However, electrode insertion is invasive, posi-
tive sensory symptoms may be troubling and efﬁcacy is
limited.
There would be signiﬁcant challenges in developing a
clinical therapeutic using our approach, mainly relating to
delivery of the GluCl channel to sensory neurons in
patients. Implicit in the ﬁndings from our nerve injury ex-
periment is the fact that GluCl efﬁcacy is directly correlated
with the level of transduction achieved. AAV is, however,
well tolerated in humans, can transfect post-mitotic neu-
rons with long lasting expression (Hadaczek et al., 2010)
and is already used in clinical trials (Kotterman and
Schaffer, 2014). GluCl is modiﬁed from a Caenorhabiditis
elegans protein and so the risk of an immune response in
humans would need to be carefully considered. This is a
major challenge for the ﬁeld of AAV gene therapy, but is
particularly pertinent when expressing a non-self transgene
in the periphery (Montgomery et al., 2016). It is encoura-
ging that long-term GluCl expression does not cause overt
injury to DRG neurons and most signiﬁcantly does not
result in cutaneous denervation in our mouse models.
However, strategies to modulate any potential immune re-
sponse [e.g. tolerance induction or immune suppression
(Mingozzi et al., 2003; Sack and Herzog, 2009)] to
GluCl would have to be considered as part of any transla-
tional pathway. There is evidence that ectopic activity de-
velops in both small and large diameter sensory afferents
and that both populations contribute to neuropathic pain
(Ossipov et al., 1999; Tarpley et al., 2004; Xu et al., 2015),
hence our logic in targeting all sensory neurons. In certain
situations, such as inﬂammatory pain (Abrahamsen et al.,
2008; Brenneis et al., 2013), there would be an argument
to restrict GluCl expression to small diameter nociceptive
afferents that would necessitate development of effective
promoters restricted to this population. The need to gener-
ate two independent AAVs expressing each subunit is a
disadvantage when trying to silence a broad range of sen-
sory neurons; however, certain paradigms can exploit this
by using two independent promoters to express the sub-
units in an intersectional manner (Haubensak et al.,
2010). Our data provide proof-of-concept that this chemo-
genetic approach can be used to deﬁne primary afferent
contributions to persistent pain states and furthermore
has translational potential to suppress hyperexcitability
and treat neuropathic pain.
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